Novel drug is potential game changer for acute lymphoblastic leukemia
A new antibody-drug conjugate (ADC) that targets B-cell acute lymphoblastic leukemia (B-ALL) is showing early promise in the fight against childhood leukemia. ALL is a cancer that involves the white blood cells of the bone marrow. It is the most common leukemia diagnosed in children and young adults.